PROCEPT BioRoboticsPRCT +4.95%70 EBIT per Share is $-1.76 as of Mar. 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $92.12 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 690 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 64.35% on this metric.
PROCEPT BioRobotics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.55.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.76.
During the past 3 years, the average EBIT per Share Growth Rate was -0.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -0.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PROCEPT BioRobotics's EBIT per Share or its related term are showing as below:
PRCT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19.3 Med: -6.4 Max: 17.4
Current: -0.9
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of PROCEPT BioRobotics was 17.40% per year. The lowest was -19.30% per year. And the median was -6.40% per year.
PRCT's 3-Year EBIT Growth Rate is ranked worse than 64.35% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.65
vs PRCT: -0.90
PROCEPT BioRobotics (NAS:PRCT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PROCEPT BioRobotics EBIT per Share Related Terms
PROCEPT BioRobotics EBIT per Share Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a EBIT per Share of $-1.76 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #444 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 64.3%.
Is PROCEPT BioRobotics' EBIT per Share too high?
PROCEPT BioRobotics' current EBIT per Share is $-1.76. Based on the distribution chart, PROCEPT BioRobotics ranks #444 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' EBIT per Share compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #444 out of 690 companies for EBIT per Share. This places PROCEPT BioRobotics in the lower half of its industry. The industry median EBIT per Share is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current EBIT per Share is $-1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $92.12, compared to a current price of $22.56 — trading 75.5% below its estimated fair value. The current EBIT per Share is $-1.76. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current EBIT per Share is $-1.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $22.56 is trading 75.5% below its estimated GF Value™ of $92.12.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
EBIT per Share: $-1.76
GF Value™: $92.12 vs. price of $22.56 (75.5% below fair value)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
